The Longevity Reality Radar
46 approaches, rated by evidence.

Lp(a) lowering drugs

Lipoprotein(a) lowering (pelacarsen / olpasiran). Heart & cardiovascular. Reviewed Jul 2026.

Cuts Lp(a) by 80 to 98% in trials, but outcome trials have not yet shown that this prevents heart attacks or strokes.

Stage
Phase 3, outcome trials
Rung: In human trials. Phase 1 to 3. Being tested in people now. Most will not make it.
Evidence grade
B
surrogate RCTs
Randomised human data on surrogate markers, or consistent large cohorts. How grades work.

What it is

siRNA / antisense drugs that silence production of Lp(a), a genetic cholesterol particle that statins can't touch and that drives heart attack and stroke risk.

The evidence

Phase 2 showed Lp(a) reductions of 80–98%; large cardiovascular outcome trials (Lp(a)HORIZON, OCEAN(a)) are reading out to prove that lowering Lp(a) actually cuts events.

What you can do today

Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Heart & cardiovascular

All 3 in Heart & cardiovascular.

  • Dietary nitrate and nitric oxideGrade B, blood pressure RCTs. Established, for blood pressure only.Lowers systolic blood pressure by about 3 to 5 mmHg in randomised trials, but there is no outcome data showing it prevents heart attacks, deaths or plaque.
  • PCSK9 base editing (VERVE-102)Grade C, small Phase 1. Phase 1.One infusion durably lowered LDL in a small Phase 1, but there is no heart-attack outcome data and the long-term safety of a permanent edit is not established.